PUBLISHER: Persistence Market Research | PRODUCT CODE: 1442652
PUBLISHER: Persistence Market Research | PRODUCT CODE: 1442652
Cardiac Biomarker Diagnostic Test Kits Market by Product Type, End-Users, & Geography (North America, Europe, Asia Pacific, Latin America, & the Middle East & Africa): Global Industry Analysis, Size, Share, Growth, Trends, & Forecast, 2023-2030
Persistence Market Research presents a comprehensive report on the global Cardiac Biomarker Diagnostic Test Kits Market analysis, provides a comprehensive overview of the cardiac biomarker diagnostics industry. This report offers insights into market dynamics, growth drivers, challenges, and emerging trends, presenting exclusive data and statistics forecasting the market's trajectory from 2023 to 2030.
The global cardiac biomarker diagnostic test kits market is forecast to expand at a CAGR of 5.4% and thereby increase from a value of US$1.7 Bn in 2023, to US$2.5 Bn by the end of 2030.
- Key Insights:
Cardiac Biomarker Diagnostic Test Kits Market Size (2023E): USD 1.7 Billion
Projected Market Value (2030F): USD 2.5 Billion
Global Market Growth Rate (CAGR 2023 to 2030): 5.4%
Historical Market Growth Rate (CAGR 2018 to 2022): 4.5%
Cardiac Biomarker Diagnostic Test Kits Market - Report Scope:
Cardiac biomarker diagnostic test kits play a crucial role in the early detection, diagnosis, and monitoring of various cardiovascular diseases (CVDs), including myocardial infarction, heart failure, and coronary artery disease. These kits detect specific biomarkers, such as troponin, creatine kinase-MB (CK-MB), and B-type natriuretic peptide (BNP), which are indicative of cardiac injury or dysfunction. The market caters to diverse healthcare settings, including hospitals, clinics, diagnostic laboratories, and ambulatory care centers. Market growth is driven by the rising prevalence of CVDs, increasing awareness about preventive healthcare, and advancements in diagnostic technologies.
- Market Growth Drivers:
The global Cardiac Biomarker Diagnostic Test Kits Market is propelled by several key factors, including the growing burden of cardiovascular diseases, aging populations, and lifestyle-related risk factors such as obesity, hypertension, and diabetes. The emphasis on early disease detection, timely intervention, and personalized treatment strategies drives the adoption of cardiac biomarker tests, facilitating risk stratification, prognosis assessment, and therapeutic monitoring for patients with CVDs. Furthermore, advancements in assay technologies, including high-sensitivity assays and point-of-care testing platforms, enhance the accuracy, sensitivity, and turnaround time of cardiac biomarker tests, fostering market growth.
- Market Restraints:
Despite robust growth prospects, the Cardiac Biomarker Diagnostic Test Kits Market faces challenges related to reimbursement policies, regulatory compliance, and competitive pricing pressures. Reimbursement constraints and healthcare budget limitations in certain regions impede market access and adoption of novel cardiac biomarker tests, particularly in resource-constrained settings. Moreover, regulatory requirements for test validation, clinical utility, and post-market surveillance impose compliance burdens on manufacturers, influencing product development timelines and market entry strategies. Addressing these challenges necessitates collaborative efforts among stakeholders to streamline regulatory pathways, expand reimbursement coverage, and ensure equitable access to cardiac biomarker diagnostics.
- Market Opportunities:
The Cardiac Biomarker Diagnostic Test Kits Market presents significant growth opportunities driven by technological innovations, market expansion strategies, and evolving healthcare paradigms. The integration of artificial intelligence (AI) and machine learning (ML) algorithms enables data-driven insights, predictive analytics, and risk stratification models, enhancing the clinical utility and prognostic value of cardiac biomarker tests. Furthermore, the growing emphasis on precision medicine and personalized healthcare drives demand for multiplex assays, novel biomarkers, and companion diagnostic tools, catering to individual patient profiles and treatment responses. Strategic partnerships, collaborations, and investments in R&D are essential to capitalize on emerging opportunities and address unmet needs in the dynamic cardiac biomarker diagnostics landscape.
Key Questions Answered in the Report:
- What are the primary factors driving the growth of the Cardiac Biomarker Diagnostic Test Kits Market globally?
- Which cardiac biomarkers and testing modalities are witnessing increased adoption and demand?
- How are technological advancements reshaping the competitive landscape of the cardiac biomarker diagnostics market?
- Who are the key players contributing to the Cardiac Biomarker Diagnostic Test Kits Market, and what strategies are they employing to maintain market relevance?
- What are the emerging trends and future prospects in the global Cardiac Biomarker Diagnostic Test Kits Market?
Competitive Intelligence and Business Strategy:
Leading players in the global Cardiac Biomarker Diagnostic Test Kits Market, including Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers, focus on innovation, portfolio expansion, and strategic collaborations to gain a competitive edge. These companies invest heavily in R&D to develop novel assays, platforms, and integrated solutions that address evolving clinical needs and market demands. Strategic acquisitions, partnerships, and licensing agreements enable market players to expand their product portfolios, enhance market penetration, and strengthen global presence. Moreover, emphasis on quality assurance, regulatory compliance, and clinical validation reinforces product credibility and customer trust in the fiercely competitive Cardiac Biomarker Diagnostic Test Kits Market landscape.
- Key Companies Profiled:
- Abbott Laboratories
- Danaher Corporation
- Bio-Rad Laboratories
Thermo Fisher Scientific, Inc.
Becton, Dickinson and Company
- F. Hoffmann-La Roche Ltd.
- Siemens AG
- BioMerieux SA
- Randox Laboratories Ltd.
- Others
Cardiac Biomarker Diagnostic Test Kits Market Research Segmentation:
The Cardiac Biomarker Diagnostic Test Kits Market encompasses a wide range of products, technologies, biomarkers, and end-user segments, catering to diverse clinical and operational requirements.
- By Product Type:
Brain Natriuretic Peptide (BNPs) Test Kits
Creatine Kinase MB (CK-MB) Test Kits
- Troponin (I&T) Tests Kits
- Myoglobin Test Kits
- Others
- By Indication:
- Angina Pectoris
- Acute Myocardial Infarction
- Congestive Heart Failure
- Others
- By End-use:
- Hospitals
- Diagnostic Laboratories
- Outpatient Clinics
Academic & Research Institutes
- By Region:
- North America
- Europe
- East Asia
- South Asia & Oceania
- Latin America
- Middle East & Africa
Table of Contents
1. Executive Summary
- 1.1. Global Cardiac Biomarker Diagnostic Test Kits Market Snapshot, 2023 and 2030
- 1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
- 1.3. Key Market Trends
- 1.4. Future Market Projections
- 1.5. Premium Market Insights
- 1.6. Industry Developments and Key Market Events
- 1.7. PMR Analysis and Recommendations
2. Market Overview
- 2.1. Market Scope and Definition
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
- 2.3. Product Type Lifecycle Analysis
- 2.4. Cardiac Biomarker Diagnostic Test Kits Market: Value Chain
- 2.4.1. List of Raw Material Supplier
- 2.4.2. List of Manufacturers
- 2.4.3. List of Distributors
- 2.4.4. List of Applications
- 2.4.5. Profitability Analysis
- 2.5. Porter Five Force's Analysis
- 2.6. Geopolitical Tensions: Market Impact
- 2.7. Macro-Economic Factors
- 2.7.1. Global Sectorial Outlook
- 2.7.2. Global GDP Growth Outlook
- 2.7.3. Global Parent Market Overview
- 2.8. Forecast Factors - Relevance and Impact
- 2.9. Regulatory and Technology Landscape
3. Global Cardiac Biomarker Diagnostic Test Kits Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
- 3.1. Key Highlights
- 3.1.1. Market Volume (Units) Projections
- 3.1.2. Market Size and Y-o-Y Growth
- 3.1.3. Absolute $ Opportunity
- 3.2. Market Size (US$ Mn) Analysis and Forecast
- 3.2.1. Historical Market Size Analysis, 2013-2016
- 3.2.2. Current Market Size Forecast, 2018-2026
- 3.3. Global Cardiac Biomarker Diagnostic Test Kits Market Outlook: Product Type
- 3.3.1. Introduction / Key Findings
- 3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Product Type, 2018 - 2022
- 3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product Type, 2023 - 2030
- 3.3.3.1. Brain Natriuretic Peptide (BNPs) Test Kits
- 3.3.3.2. Creatine Kinase MB (CK-MB) Test Kits
- 3.3.3.3. Troponin (I&T) Tests Kits
- 3.3.3.4. Myoglobin Test Kits
- 3.3.3.5. Others
- 3.4. Market Attractiveness Analysis: Product Type
- 3.5. Global Cardiac Biomarker Diagnostic Test Kits Market Outlook: Indication
- 3.5.1. Introduction / Key Findings
- 3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Indication, 2018 - 2022
- 3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2023 - 2030
- 3.5.3.1. Angina Pectoris
- 3.5.3.2. Acute Myocardial Infarction
- 3.5.3.3. Congestive Heart Failure
- 3.5.3.4. Others
- 3.6. Market Attractiveness Analysis: Indication
- 3.7. Global Cardiac Biomarker Diagnostic Test Kits Market Outlook: End-Use
- 3.7.1. Introduction / Key Findings
- 3.7.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By End-Use, 2018 - 2022
- 3.7.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By End-Use, 2023 - 2030
- 3.7.3.1. Hospitals
- 3.7.3.2. Diagnostic Laboratories
- 3.7.3.3. Outpatient Clinics
- 3.7.3.4. Academic & Research Institutes
- 3.8. Market Attractiveness Analysis: End-Use
4. Global Cardiac Biomarker Diagnostic Test Kits Market Outlook: Region
- 4.1. Key Highlights
- 4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
- 4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
- 4.3.1. North America
- 4.3.2. Europe
- 4.3.3. East Asia
- 4.3.4. South Asia & Pacific
- 4.3.5. Latin America
- 4.3.6. Middle East & Africa (MEA)
- 4.4. Market Attractiveness Analysis: Region
5. North America Cardiac Biomarker Diagnostic Test Kits Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
- 5.1. Key Highlights
- 5.2. Pricing Analysis
- 5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 5.3.1. By Country
- 5.3.2. By Product Type
- 5.3.3. By Indication
- 5.3.4. By End-Use
- 5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 5.4.1. U.S.
- 5.4.2. Canada
- 5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product Type, 2023 - 2030
- 5.5.1. Brain Natriuretic Peptide (BNPs) Test Kits
- 5.5.2. Creatine Kinase MB (CK-MB) Test Kits
- 5.5.3. Troponin (I&T) Tests Kits
- 5.5.4. Myoglobin Test Kits
- 5.5.5. Others
- 5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2023 - 2030
- 5.6.1. Angina Pectoris
- 5.6.2. Acute Myocardial Infarction
- 5.6.3. Congestive Heart Failure
- 5.6.4. Others
- 5.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By End-Use, 2023 - 2030
- 5.7.1. Hospitals
- 5.7.2. Diagnostic Laboratories
- 5.7.3. Outpatient Clinics
- 5.7.4. Academic & Research Institutes
- 5.8. Market Attractiveness Analysis
6. Europe Cardiac Biomarker Diagnostic Test Kits Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
- 6.1. Key Highlights
- 6.2. Pricing Analysis
- 6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 6.3.1. By Country
- 6.3.2. By Product Type
- 6.3.3. By Indication
- 6.3.4. By End-Use
- 6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 6.4.1. Germany
- 6.4.2. France
- 6.4.3. U.K.
- 6.4.4. Italy
- 6.4.5. Spain
- 6.4.6. Russia
- 6.4.7. Turkey
- 6.4.8. Rest of Europe
- 6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product Type, 2023 - 2030
- 6.5.1. Brain Natriuretic Peptide (BNPs) Test Kits
- 6.5.2. Creatine Kinase MB (CK-MB) Test Kits
- 6.5.3. Troponin (I&T) Tests Kits
- 6.5.4. Myoglobin Test Kits
- 6.5.5. Others
- 6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2023 - 2030
- 6.6.1. Angina Pectoris
- 6.6.2. Acute Myocardial Infarction
- 6.6.3. Congestive Heart Failure
- 6.6.4. Others
- 6.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By End-Use, 2023 - 2030
- 6.7.1. Hospitals
- 6.7.2. Diagnostic Laboratories
- 6.7.3. Outpatient Clinics
- 6.7.4. Academic & Research Institutes
- 6.8. Market Attractiveness Analysis
7. East Asia Cardiac Biomarker Diagnostic Test Kits Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
- 7.1. Key Highlights
- 7.2. Pricing Analysis
- 7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 7.3.1. By Country
- 7.3.2. By Product Type
- 7.3.3. By Indication
- 7.3.4. By End-Use
- 7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 7.4.1. China
- 7.4.2. Japan
- 7.4.3. South Korea
- 7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product Type, 2023 - 2030
- 7.5.1. Brain Natriuretic Peptide (BNPs) Test Kits
- 7.5.2. Creatine Kinase MB (CK-MB) Test Kits
- 7.5.3. Troponin (I&T) Tests Kits
- 7.5.4. Myoglobin Test Kits
- 7.5.5. Others
- 7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2023 - 2030
- 7.6.1. Angina Pectoris
- 7.6.2. Acute Myocardial Infarction
- 7.6.3. Congestive Heart Failure
- 7.6.4. Others
- 7.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By End-Use, 2023 - 2030
- 7.7.1. Hospitals
- 7.7.2. Diagnostic Laboratories
- 7.7.3. Outpatient Clinics
- 7.7.4. Academic & Research Institutes
- 7.8. Market Attractiveness Analysis
8. South Asia & Oceania Cardiac Biomarker Diagnostic Test Kits Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
- 8.1. Key Highlights
- 8.2. Pricing Analysis
- 8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 8.3.1. By Country
- 8.3.2. By Product Type
- 8.3.3. By Indication
- 8.3.4. By End-Use
- 8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 8.4.1. India
- 8.4.2. Southeast Asia
- 8.4.3. ANZ
- 8.4.4. Rest of South Asia & Oceania
- 8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product Type, 2023 - 2030
- 8.5.1. Brain Natriuretic Peptide (BNPs) Test Kits
- 8.5.2. Creatine Kinase MB (CK-MB) Test Kits
- 8.5.3. Troponin (I&T) Tests Kits
- 8.5.4. Myoglobin Test Kits
- 8.5.5. Others
- 8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2023 - 2030
- 8.6.1. Angina Pectoris
- 8.6.2. Acute Myocardial Infarction
- 8.6.3. Congestive Heart Failure
- 8.6.4. Others
- 8.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By End-Use, 2023 - 2030
- 8.7.1. Hospitals
- 8.7.2. Diagnostic Laboratories
- 8.7.3. Outpatient Clinics
- 8.7.4. Academic & Research Institutes
- 8.8. Market Attractiveness Analysis
9. Latin America Cardiac Biomarker Diagnostic Test Kits Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
- 9.1. Key Highlights
- 9.2. Pricing Analysis
- 9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 9.3.1. By Country
- 9.3.2. By Product Type
- 9.3.3. By Indication
- 9.3.4. By End-Use
- 9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 9.4.1. Brazil
- 9.4.2. Mexico
- 9.4.3. Rest of Latin America
- 9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product Type, 2023 - 2030
- 9.5.1. Brain Natriuretic Peptide (BNPs) Test Kits
- 9.5.2. Creatine Kinase MB (CK-MB) Test Kits
- 9.5.3. Troponin (I&T) Tests Kits
- 9.5.4. Myoglobin Test Kits
- 9.5.5. Others
- 9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2023 - 2030
- 9.6.1. Angina Pectoris
- 9.6.2. Acute Myocardial Infarction
- 9.6.3. Congestive Heart Failure
- 9.6.4. Others
- 9.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By End-Use, 2023 - 2030
- 9.7.1. Hospitals
- 9.7.2. Diagnostic Laboratories
- 9.7.3. Outpatient Clinics
- 9.7.4. Academic & Research Institutes
- 9.8. Market Attractiveness Analysis
10. Middle East & Africa Cardiac Biomarker Diagnostic Test Kits Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
- 10.1. Key Highlights
- 10.2. Pricing Analysis
- 10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 10.3.1. By Country
- 10.3.2. By Product Type
- 10.3.3. By Indication
- 10.3.4. By End-Use
- 10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 10.4.1. GCC
- 10.4.2. Egypt
- 10.4.3. South Africa
- 10.4.4. Northern Africa
- 10.4.5. Rest of Middle East & Africa
- 10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product Type, 2023 - 2030
- 10.5.1. Brain Natriuretic Peptide (BNPs) Test Kits
- 10.5.2. Creatine Kinase MB (CK-MB) Test Kits
- 10.5.3. Troponin (I&T) Tests Kits
- 10.5.4. Myoglobin Test Kits
- 10.5.5. Others
- 10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2023 - 2030
- 10.6.1. Angina Pectoris
- 10.6.2. Acute Myocardial Infarction
- 10.6.3. Congestive Heart Failure
- 10.6.4. Others
- 10.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By End-Use, 2023 - 2030
- 10.7.1. Hospitals
- 10.7.2. Diagnostic Laboratories
- 10.7.3. Outpatient Clinics
- 10.7.4. Academic & Research Institutes
- 10.8. Market Attractiveness Analysis
11. Competition Landscape
- 11.1. Market Share Analysis, 2022
- 11.2. Market Structure
- 11.2.1. Competition Intensity Mapping By Market
- 11.2.2. Competition Creatine Kinase MB (CK-MB) Test Kits
- 11.2.3. Apparent Product Capacity
- 11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 11.3.1. Abbott Laboratories
- 11.3.1.1. Overview
- 11.3.1.2. Segments and Product
- 11.3.1.3. Key Financials
- 11.3.1.4. Market Developments
- 11.3.1.5. Market Strategy
- 11.3.2. Danaher Corporation
- 11.3.2.1. Overview
- 11.3.2.2. Segments and Product
- 11.3.2.3. Key Financials
- 11.3.2.4. Market Developments
- 11.3.2.5. Market Strategy
- 11.3.3. Bio-Rad Laboratories
- 11.3.3.1. Overview
- 11.3.3.2. Segments and Product
- 11.3.3.3. Key Financials
- 11.3.3.4. Market Developments
- 11.3.3.5. Market Strategy
- 11.3.4. Thermo Fisher Scientific, Inc.
- 11.3.4.1. Overview
- 11.3.4.2. Segments and Product
- 11.3.4.3. Key Financials
- 11.3.4.4. Market Developments
- 11.3.4.5. Market Strategy
- 11.3.5. Becton, Dickinson and Company
- 11.3.5.1. Overview
- 11.3.5.2. Segments and Product
- 11.3.5.3. Key Financials
- 11.3.5.4. Market Developments
- 11.3.5.5. Market Strategy
- 11.3.6. F. Hoffmann-La Roche Ltd.
- 11.3.6.1. Overview
- 11.3.6.2. Segments and Product
- 11.3.6.3. Key Financials
- 11.3.6.4. Market Developments
- 11.3.6.5. Market Strategy
- 11.3.7. Siemens AG
- 11.3.7.1. Overview
- 11.3.7.2. Segments and Product
- 11.3.7.3. Key Financials
- 11.3.7.4. Market Developments
- 11.3.7.5. Market Strategy
- 11.3.8. BioMerieux SA
- 11.3.8.1. Overview
- 11.3.8.2. Segments and Product
- 11.3.8.3. Key Financials
- 11.3.8.4. Market Developments
- 11.3.8.5. Market Strategy
- 11.3.9. Randox Laboratories Ltd.
- 11.3.9.1. Overview
- 11.3.9.2. Segments and Product
- 11.3.9.3. Key Financials
- 11.3.9.4. Market Developments
- 11.3.9.5. Market Strategy
- 11.3.10. Others
- 11.3.1. Abbott Laboratories
12. Appendix
- 12.1. Research Methodology
- 12.2. Research Assumptions
- 12.3. Acronyms and Abbreviations
